Although the current replacement enzymes are serving CF patients well, there is now an opportunity to further improve nutrition with the development of a new enzyme product. This new product, TheraCLEC-Total , is produced by using the latest enzyme purification and stabilization techniques and will offer several potential advantages over existing therapies to treat pancreatic problems. Specifically, the product will be designed to be pure and potent, and will allow precise dosing. Payments are tied to successful completion of specified research milestones at checkpoints along the way. If the project is terminated early for any reason, the payments to Altus will be limited.
New technology makes a pure form possible.
Potent TheraCLEC-Total will be a crystallized form of enzymes that remain active throughout the intestinal tract. Therefore, far fewer capsules will need to be taken with each meal. Hopefully, this will make it easier for patients to take enzymes and ultimately improve their nutritional status. The amount of enzymes in currently available products can vary somewhat because of the way the manufacturing process varies. The manufacturing process for TheraCLEC will enable precise amounts of enzyme to be placed in each capsule, allowing more precise dosing.